A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Dezapelisib (Primary) ; Itacitinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 07 Sep 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 25 Apr 2018 Final results (data cutoff: Dec 1, 2016), published in the Blood